Purpose: To observe the short-term dynamic change in serum CXC chemokine ligand-10 (CXCL10) levels in patients with Graves' disease (GD) before and a er iodine therapy and to analyze the relationship between CXCL10 levels and clinical disease indices.
Graves' disease (GD), which causes hyperthyroidism, is a common autoimmune disease of the thyroid. GD shows striking immunological disorders including the production of activating antibodies, abnormalities in the circulating T cell population and goitres with lymphocytic in ltration. e thyroid antibodies may stimulate thyroid function, resulting in unrestrained thyrocyte growth, excessive thyroid hormone production, thyrotoxicosis, di use hyperplasia and enlargement of the thyroid gland. Recently, it has been reported that T cells, involved in GD, may change throughout the course of the disease, and that T cells are critical in the induction, development and maintenance of GD.
Chemokines are a group of low molecular weight peptides that are able to recruit speci c leukocyte subtypes to in ammation sites [1] . Several studies suggest that chemokines may be crucial for the recruitment and/or homing of T cells in the in amed tissues. Recent experimental evidence has shown that CXC-αchemokines, especially CXC chemokine ligand-10/ inducing protein-10 (CXCL-10/IP-10), play an important role in the initial phases of autoimmune thyroid disorders [2] [3] [4] [5] [6] . In GD, CXCR3, the receptor of CXCL-10, is expressed in endothelial and in ammatory cells , thyrocytes [2, 5] and serum CXCL10 levels are signi cantly increased in GD patients with recent onset of disease [2] .
Iodine-131 ( 131 I) therapy is increasingly being used as a rst-line treatment for hyperthyroidism in Graves' disease (GD). Previous studies have evaluated the e ect of radioactive iodine therapy on cytokine production in GD patients, but with contrasting results [7, 8] . e aim of our study was to identify the short-term e ect of radioiodine on serum CXCL10 levels and to evaluate the relationship between CXCL10 levels and clinical disease indices.
Materials and Methods

Patients
GD was diagnosed on the basis of clinical, biochemical and immunological features, as well as from scintiscans. e selected 43 GD patients in this study were newly diagnosed and were not being treated with antithyroid drugs. Patients were referred to the inpatient clinic at the People's Hospital of Linyi City for rst-time radioiodine treatment of hyperthyroidism: 34 women and 9 men, aged 20-57 years (mean, 35.88±9.79 years). e duration of the disease was from two weeks to two years (mean, 6.06 months). e control group matched approximately for age and sex comprised 23 female and 7 male subjects, aged 22-54 years (mean, 36.28±7.26 years) who were all in good health. All subjects gave informed consent. e study was approved by ethical committee review. All GD patients were treated with a single oral dose of radioiodine ( 131 I).
Blood samples
Blood were obtained from control group and patients shortly before radioiodine therapy and on days six, 14 and 60 posttherapy. e blood samples were centrifuged at 2500 g for 15 minutes and the supernatants were stored at -80°C for later testing.
yroid function tests
Free T4, Free T3 and TSH were measured by chemiluminometric immunoassay. Serum thyroid peroxidase antibodies (TPOAb) were measured by radioimmunoassay. Serum CXCL10/IP-10 levels were measured by ELISA (human IP-10 immunoassay, R&D Systems, USA). Intra-and interassay coefcients of variation (CV) were all below 10%.
Statistical analysis
Di erences between patients and controls were analyzed by Student's t test, and T paired test were used in the analysis among patients at di erent time points before and a er treatment. Correlations among CXCL10 levels, thyroid function and autoantibody levels were determined by linear regression analysis. P value of less than 0.05 was accepted as statistically signi cant. Statistical analyses were carried out by SAS so ware (version 8.0).
Results
e levels of FT3 and FT4 in the newly diagnosed GD patients were signi cantly higher immediately before therapy (mean, 24.04±5.22 pmol/L and 77.42±28.99 pmol/L, respectively) compared with those of the control group (mean, 4.66±0.49 pmol/L, 13.65±1.23 pmol/L, respectively) and fell to 7.00±5.81 pmol/L and 19.87±7.13 pmol/L, respectively by day 60 a er the therapy. TSH in patients before treatment was lower than that of control group (mean, 0.006±0.001 uIU/L, 2.21±1.11 uIU/L, respectively) and became nearly normal (5.76±1.56 uIU/L) on day 60 (Fig.1A) . e serum TPOAb levels increased gradually a er therapy and became positive in 86.05% of subjects on day 60 a er therapy (Fig.1B) .
e serum CXCL10 levels were signi cantly higher in newly diagnosed GD patients in comparison with the control group (t=-3.94 P<0.01) ( Fig.2A) . Serum CXCL10 levels increased slightly on the sixth day a er radioactive iodine decreased by day 14 to levels not signi cantly di erent from pretreatment levels, then decreased further to below pretreatment levels by day 60 a er therapy (t=4.212 P<0.01) (Fig.2B) . Prior to therapy, the serum levels of CXCL10 in GD patients with exophthalmia were higher than those without exophthalmia (Fig.2C ).
Correlation analysis
ere was no correlation between levels of CXCL10 with FT3 FT4 or TSH at any time point (P>0.05). TPOAb level was positively related with CXCL10 (r=0.50, P<0.01).
Discussion
Iodine-131 ( 131 I) therapy is increasingly being used as a rstline treatment for hyperthyroidism in Graves' disease (GD).
ere is general consensus that 131 I constitutes a safe and highly cost-e ective therapeutic option, devoid of major side e ects. Nevertheless, there are some aspects related to 131 I therapy that remain controversial (9) . In our study, thyroid hormone levels become nearly normal by day 60 and the serum levels of TPOAb increase gradually a er therapy. e destruction of thyroid follicular cells and the release of thyroid antigens a er 131 I treatment, with the ensuing e ects on circulating markers of autoimmunity [9] , is the probable cause of these changes in hormone and antibody levels. erefore, it is reasonable to expect that chemokine pro les and the autoimmune process might also be a ected.
Chemokines are a family of cytokines initially characterized by their capacity to induce chemotaxis, or directed leukocyte migration [10, 11] . CXCL10/ IP -10 are CXC chemokines that are induced by interferon-γ during in ammation and that display potent lymphocyte chemotactic activity [12, 13] . e CXCR3 chemokine receptor is speci c for the CXC chemokines CXCL10/ IP -10 [13, 14] . CXCL10/ IP -10 binding to the CXCR3 receptor is considered important in delivering speci c signals for selective homing of activated/e ector cells to some in ammatory sites [15] . Recent studies have implicated both mRNA and protein expression of the chemokines CXCL10/ IP -10, and its receptor, CXCR3, could be readily detected in the thyroid glands of patients su ering from GD. In addition, CXCL10/ IP -10 levels can be measured in the serum of GD patients. Expression of CXCL10/ IP -10 and CXCR3 has been shown to be poor or absent in normal thyroid tissue from patients undergoing thyroidectomy. CXCL10/ IP -10, usually localized to in ltrating lymphocytes and macrophages, as well as to resident epithelial follicular cells, maximal expression of CXCL10/ IP -10 was found in the thyroid gland of patients with recent-onset GD and was correlated with interferon-γ [2] . Taken together, these data suggest a pathogenic role for these chemokines in the recruitment of activated T cells in in amed thyroid tissue and suggest that the detection of CXCL10/ IP -10 may represent a useful clinical marker in GD. in GD patients before radioiodine therapy and 60 days a er therapy; radioiodine therapy and 60 days a er therapy.
Antonelli et al. have shown that in patients with Graves' disease, serum CXCL10 is signi cantly reduced a er thyroidectomy [16] or 131 I therapy [17] . ese results suggest that the thyroid gland is the main source of circulating CXCL10 in patients with Graves' disease. Antonelli et al. also found that serum levels of CXCL10, evaluated in hyperthyroid GD patients at the time of diagnosis, was reduced signi cantly a er restoration of euthyroidism by MMI treatment; however, patients with toxic nodular goiter showed no obvious change when rendered euthyroid by the same medication. erefore, the marked reduction in circulating concentrations of CXCL10 in GD patients a er MMI treatment could be interpreted as resulting from an immunomodulatory action of the drug rather than from the restoration of euthyroidism [18, 19] . Increased plasma CXCL10 would promote in ltration of activated lymphocytes into the thyroid gland, and represents a potential indicator of disease activity in Graves' disease; thus, increased circulating CXCL10 in patients with Graves' disease may be speci cally sustained by the autoimmune, in ammatory process.
In present study, the serum CXCL10 levels were signicantly higher in newly diagnosed GD patients in comparions with the control group. Of note, a signi cant correlation was observed between serum levels of CXCL10 and TPOAb but not with the thyroid hormone levels. e levels of CXCL10, which rst increased on day six a er treatment with radioactive iodine, may relate to the autoimmune response induced by 131 I.
e subsequent reduction of circulating CXCL10 levels a er destruction of thyroid tissue by 131 I therapy can be explained by removal of the large part of either intrathyroidal lymphocytes and/or thyrocytes, which may be the main source of CXCL10.
us, the dynamic change of CXCL10 levels can be considered a marker of a more aggressive autoimmune process leading to thyroid destruction [3, 4] .
Signi cantly higher pre-therapy circulating CXCL10 levels were also seen in GD patients with ophthalmopathy (GO) compared with the patients without ophthalmopathy. It is well known that cytokines play a crucial role in the pathogenesis of GO; Antonelli et al. showed similar results and a signi cant association between CXCL10 levels and activity of GO , suggesting that the presence of orbital in ammation may be responsible for an increase in circulating concentrations of CXCL10 (20) . It is worth noting that there are currently no established, reliable serum markers to evaluate the activity in GO. us, it would be helpful to investigate the clinical signicance of serum chemokine detection [21] .
e present study con rmed that CXCL10 participates in the short term e ects of radioactive iodine therapy and shows a strong association with the autoimmune process; therefore, observation of the dynamics of these changes in serum CXCL10 levels may be helpful to understand the in ammatory changes a er iodine treatment. A longitudinal study would be required to determine the changes in CXCL10 and thyroid autoantibody levels, and to observe the e ects of these changes on clinical outcome a er 131 I therapy.
